TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07211997: FebriDx® Pediatric Validation Study

Sponsor: Lumos Diagnostics · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 800 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$9,408,000

Rescue Site Savings

+$6,203,400

Unlock Full NCT07211997 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07211997 Rescue Dossier →